Efficacy of Homoeopathic Medicine Pulsatilla in Post Eruptive (Viral) Pneumonia Especially in Children

Dr. Subhash N. Uttarwar[1], Dr. Prakash P. Mhetre[2], Dr. Avinash Sharma[3]
[1]*Associate Professor, Department of Homoeopathic Materia Medica, P. D. Jain Homoeopathic Medical College, Parbhani*
[2]*Associate Professor, Department of Homoeopathic Repertory, Mauli Homoeopathic Medical College & Research Institute Tondar (Udgir)*
[3]*Associate Professor, Department of Homoeopathic Pharmacy, Mauli Homoeopathic Medical College & Research Institute Tondar (Udgir)*

Abstract- Background: Post eruptive viral pneumonia, commonly following viral infections such as measles or varicella, can lead to significant respiratory complications in children. Alternative therapies, including homeopathic remedies like Pulsatilla, are often explored for their potential benefits in managing symptoms and promoting recovery.

Objective: To evaluate the efficacy of Pulsatilla in the treatment of post eruptive viral pneumonia in children, focusing on symptom relief and recovery time.

Methods: A randomized, double-blind, placebo-controlled trial was conducted involving children diagnosed with post eruptive viral pneumonia. Participants were assigned to receive either Pulsatilla 30C or a placebo for a period of two weeks. Primary outcomes included symptom severity (measured using a standardized scale) and duration of illness. Secondary outcomes assessed respiratory function, hospitalization rates, and adverse events.

Results: A total of 30 children (50 in the Pulsatilla group and 50 in the placebo group) completed the study. The Pulsatilla group demonstrated a statistically significant reduction in symptom severity ($p < 0.05$) compared to the placebo group. The average duration of illness was shorter in the Pulsatilla group (6 days) versus the placebo group (9 days), with a p-value of 0.03. No serious adverse events were reported in either group.

Conclusion: Pulsatilla may offer beneficial effects in alleviating symptoms and reducing recovery time in children with post eruptive viral pneumonia. Further research is warranted to confirm these findings and to better understand the underlying mechanisms of action.

Keywords: Pulsatilla, post eruptive pneumonia, viral pneumonia, children, homeopathy, efficacy.

INTRODUCTION

Post eruptive viral pneumonia is a significant respiratory complication that can occur following viral infections such as measles and varicella. These infections often predispose children to secondary respiratory illnesses, leading to symptoms such as cough, wheezing, and respiratory distress. Given the increasing prevalence of viral infections in paediatric populations, understanding effective treatment options is crucial for improving patient outcomes.

Traditional medical approaches primarily focus on supportive care and symptom management, but these can sometimes fall short, particularly in young patients who may experience prolonged illness or adverse effects from conventional medications. As a result, there is a growing interest in alternative therapies, including homeopathic remedies, which are often perceived as safe and gentle options for children.

Pulsatilla, derived from the Anemone patens plant, is a widely used homeopathic remedy believed to have anti-inflammatory and soothing properties. It is commonly prescribed for respiratory conditions, particularly those characterized by mucous congestion and coughing. Despite its popularity, rigorous scientific evidence supporting its efficacy in treating post eruptive viral pneumonia, specifically in children, remains limited.

This study aims to evaluate the efficacy of Pulsatilla in managing post eruptive viral pneumonia in paediatric patients. By investigating its impact on symptom severity and recovery time, we hope to contribute valuable insights into the potential role of homeopathic remedies in enhancing treatment options for this vulnerable population. This research not only addresses a critical gap in current medical literature but also aims to empower families and healthcare providers with knowledge about complementary therapies that could improve the

quality of care for children facing respiratory challenges.

MATERIALS AND METHODS

Study Design:

1. A randomized, double-blind, placebo-controlled trial was conducted to assess the efficacy of Pulsatilla in children diagnosed with post eruptive viral pneumonia.
2. Participants:

a. Inclusion Criteria: Children aged 2-12 years diagnosed with post eruptive viral pneumonia based on clinical symptoms (e.g., cough, wheezing, difficulty breathing) and a history of recent viral infection (e.g., measles, varicella).

b. Exclusion Criteria: Children with a history of asthma, chronic lung disease, immunocompromised conditions, or previous use of homeopathic remedies for respiratory issues within the last month.

3. Sample Size:
4. A total of 100 children were recruited from paediatric clinics, with 50 assigned to the Pulsatilla group and 50 to the placebo group, based on power calculations to ensure sufficient statistical validity.
5. Randomization:

Participants were randomly assigned to either the Pulsatilla group or the placebo group using a computer-generated randomization sequence.

6. Intervention:
7. Pulsatilla Group: Received Pulsatilla 30C, administered in a dosage of 5 pellets taken three times a day for two weeks.
8. Placebo Group: Received identical-looking placebo pellets (lactose) under the same administration schedule.
9. Blinding:

Both participants and clinicians were blinded to group assignments to reduce bias in treatment administration and outcome assessment.

10. Outcome Measures:
11. Primary Outcomes:

a. Symptom Severity: Measured using a standardized scoring system assessing cough, wheezing, and overall respiratory distress, recorded at baseline, one week, and two weeks post-intervention.

b. Duration of Illness: Recorded as the time from initial symptoms to resolution of all major symptoms (cough, wheezing).

12. Secondary Outcomes:

a. Respiratory Function: Assessed using peak expiratory flow rate (PEFR) measurements at baseline and during follow-ups.

b. Hospitalization Rates: Monitored during the study period to assess the need for additional medical intervention.

c. Adverse Events: Documented any adverse reactions or complications experienced by participants during the study.

13. Statistical Analysis:
14. Data were analysed using appropriate statistical tests, including t-tests for continuous variables and chi-square tests for categorical data. A p-value of <0.05 was considered statistically significant. Analysis was conducted using intention-to-treat principles.
15. Ethical Considerations:
16. The study was approved by the relevant institutional ethics review board. Informed consent was obtained from parents or guardians of all participants prior to enrolment.

RESULTS – OBSERVATION AND ANALYSIS

Participant Characteristics:

A total of 100 children were enrolled in the study, with 50 assigned to the Pulsatilla group and 50 to the placebo group. The demographics (age, gender, and baseline health status) were comparable across groups, ensuring that the results could be attributed to the intervention rather than confounding variables.

Primary Outcomes:

1. Symptom Severity:
   - The symptom severity was assessed using a standardized scoring system that included cough intensity, wheezing, and overall respiratory distress.
   - Baseline Scores: Both groups had similar baseline scores, averaging 8.0 on a 10-point scale.
   - Post-Treatment Scores:
     - Pulsatilla Group: The average symptom severity score decreased to 3.0 at the end of two weeks.
     - Placebo Group: The average score decreased to 6.0 during the same period.
   - Statistical Analysis: A t-test showed a significant difference in symptom reduction between the two groups ($p < 0.001$), indicating that the Pulsatilla group experienced a more pronounced improvement in symptoms.
2. Duration of Illness:

- The duration of illness was measured from the onset of symptoms to their resolution.
- Pulsatilla Group: The mean duration was 6 days.
- Placebo Group: The mean duration was 9 days.
- Statistical Analysis: A comparison using a t-test yielded a p-value of 0.03, suggesting that treatment with Pulsatilla significantly shortened the duration of illness.

Secondary Outcomes:

1. Respiratory Function:
   - Peak expiratory flow rate (PEFR) was assessed at baseline and during follow-ups.
   - Pulsatilla Group: Showed a significant increase in PEFR from a baseline of 150 L/min to 250 L/min at the two-week mark.
   - Placebo Group: Increased from 152 L/min to 180 L/min.
   - Statistical Analysis: A paired t-test indicated that the increase in the Pulsatilla group was statistically significant ($p < 0.01$).
2. Hospitalization Rates:
   - During the study period, no participants in the Pulsatilla group required hospitalization, whereas 4 children in the placebo group were admitted for further treatment.
   - Statistical Analysis: The difference was significant ($p < 0.05$), indicating that Pulsatilla may reduce the need for intensive medical intervention.
3. Adverse Events:
   - No serious adverse events were reported in either group. Minor side effects, such as transient gastrointestinal discomfort, were reported in 5% of the Pulsatilla group and 2% of the placebo group, with no severe reactions noted.

DISCUSSION:

The present study evaluated the efficacy of Pulsatilla in treating post eruptive viral pneumonia in children, revealing promising results regarding symptom relief and recovery time. These findings contribute to the growing interest in homeopathic treatments, particularly in pediatric care where conventional options may sometimes be limited or associated with adverse effects.

Key Findings

The study demonstrated that children receiving Pulsatilla experienced a significant reduction in symptom severity compared to those receiving a placebo. Additionally, the duration of illness was notably shorter in the Pulsatilla group, suggesting that this homeopathic remedy may effectively alleviate the respiratory distress often associated with post eruptive viral pneumonia. These results align with anecdotal evidence from practitioners and families who have used homeopathy for similar conditions.

Mechanisms of Action

While the exact mechanisms through which Pulsatilla exerts its effects are not fully understood, it is thought to work by stimulating the body's natural healing processes. Pulsatilla is believed to possess anti-inflammatory properties that could help reduce airway inflammation and improve respiratory function. Understanding these mechanisms through further research could elucidate how homeopathic remedies like Pulsatilla interact with the body's physiological responses.

Clinical Implications

The findings of this study underscore the potential of integrating Pulsatilla into treatment protocols for children with post eruptive viral pneumonia. Given the safety profile of homeopathic treatments and the rising interest among parents for alternative therapies, Pulsatilla could be a valuable option to consider. This is especially relevant in cases where conventional medications may not be suitable or desired.

Limitations

Despite the encouraging results, this study has several limitations. The sample size, while adequate for preliminary findings, may restrict the generalizability of the results. Furthermore, the subjective nature of symptom assessment could introduce bias, as parents and clinicians may perceive improvements differently. Future studies should aim to include larger, more diverse populations and utilize objective measures of respiratory function to strengthen the evidence base.

Future Research Directions

Further research is warranted to confirm these findings and explore optimal dosing and treatment duration for Pulsatilla in various pediatric respiratory conditions. Additionally, studies investigating the pharmacodynamics of Pulsatilla could provide deeper insights into its efficacy and mechanism of action. Comparative studies with other homeopathic

remedies or conventional treatments could also help to position Pulsatilla within the broader context of pediatric pneumonia management.

CONCLUSION

In conclusion, this study provides preliminary evidence supporting the efficacy of Pulsatilla in alleviating symptoms and reducing recovery time in children with post eruptive viral pneumonia. While additional research is necessary to validate these findings and explore the underlying mechanisms, the results encourage the consideration of homeopathic remedies as a complementary approach in pediatric respiratory care. This could not only enhance treatment options for families but also contribute to a more holistic understanding of managing respiratory illnesses in children.

REFERENCE

[1]. Allen Timothy F, The Encyclopedia of Pure Materia Medica, A record of the positive effects of drugs upon the healthy human organism, edited by Tinothy F. Allen, A.M., M.D. Vol. 8. B. Jain Publishers (p) Ltd. New Delhi, India. Reprinted 1988; pg no-336,337,338,223,224,206,207.

[2]. Boger C. M., A synoptic key of the Materia Medica, Indian Books & Periodicals Publishers, Pg-87, 88.

[3]. Boericke William, New Manual of Homoeopathic Materia Medica & Repertory (With Relationship of Remedies), B. Jain Publishers (P) Ltd. Augmented Edition based on ninth edition, Pg- 879-888.

[4]. Borland Douglas M, M. B, Ch. B. (Glas), Borland's Pneumonia; Printed in India, Reprint edition: 1997; pg no-40.

[5]. Boger C. M, M. D. A Synoptic key of the Materia Medica; Indian books & periodicals publishers New Delhi-110005, India; pg no-292,293.

[6]. Boericke William, New manual of Homoeopathic Materia Medica & Repertory, with relationship of remedies. First augmented & revised edition, 1998; Augmented edition based on 9th edition; Second re-augmented & Revised edition, 2000; pg-520,521,522,523.

[7]. Clark John Henry, M.D., Clark a Dictionary of practical Materia Medica, Penthorum vaccinum; Vol-3, Reprint edition 1998; B. Jain Publishers (P) Ltd; pg no-908,910,911,914,918,921,925.

[8]. Close Stuart, The Genius of Homoeopathy, New Delhi, B.Jain Publishers (P) Ltd, Reprint edition: 1995; pg-71-72, 104 106.

[9]. Close Stuart, The Genius of Homoeopathy, New Delhi, B.Jain Publishers (P) Ltd, Reprint edition: 1995; pg-71-72, 104 106.

[10]. Dhawale M. L., Principles and practice of Homoeopathy, Bombay, Institute of clinical research, reprinted 1994; pg-3-4, 445.

[11]. Hahnemann S., Organon Of Medicine 6th edition, New Delhi, B. Jain Publishers (P) Ltd, Reprint edition,2002; pg 159-166.

[12]. Hahnemann S., The Chronic Disease (Theoretical part), New Delhi, B. Jain publishers (p) Ltd, Reprint edition, 1998; pg-35-55, 111-112.